Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Fischl

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individualsH Z Bass, W D Hardy, R T Mitsuyasu, et al.
Archives of Internal Medicine|May 8, 1995
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials GroupR Dolin, D A Amato, M A Fischl, et al.
The New England Journal of Medicine|June 27, 1985
Prevalence of HTLV-III/LAV antibodies among HaitiansA E Pitchenik, T J Spira, R Elie, et al.
Journal of Acquired Immune Deficiency Syndromes|February 1, 1994
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3M A Fischl, L Resnick, R Coombs, et al.
Annals of Neurology|April 1, 1993
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials GroupJ J Sidtis, C Gatsonis, R W Price, et al.
Antiviral Research|April 25, 2000
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teamsG D Morse, R C Reichman, M A Fischl, et al.
Annals of Internal Medicine|May 15, 1990
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials GroupM A Fischl, D D Richman, N Hansen, et al.
Annals of Internal Medicine|November 1, 1992
Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trialsD H Henry, G N Beall, C A Benson, et al.
JAMA|November 3, 1989
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working GroupM A Fischl, D D Richman, D M Causey, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 2, 1998
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study TeamK Henry, A Erice, C Tierney, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individualsH Z Bass, W D Hardy, R T Mitsuyasu, et al.
Archives of Internal Medicine|May 8, 1995
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials GroupR Dolin, D A Amato, M A Fischl, et al.
The New England Journal of Medicine|June 27, 1985
Prevalence of HTLV-III/LAV antibodies among HaitiansA E Pitchenik, T J Spira, R Elie, et al.
Journal of Acquired Immune Deficiency Syndromes|February 1, 1994
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3M A Fischl, L Resnick, R Coombs, et al.
Annals of Neurology|April 1, 1993
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials GroupJ J Sidtis, C Gatsonis, R W Price, et al.
Antiviral Research|April 25, 2000
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teamsG D Morse, R C Reichman, M A Fischl, et al.
Annals of Internal Medicine|May 15, 1990
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials GroupM A Fischl, D D Richman, N Hansen, et al.
Annals of Internal Medicine|November 1, 1992
Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trialsD H Henry, G N Beall, C A Benson, et al.
JAMA|November 3, 1989
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working GroupM A Fischl, D D Richman, D M Causey, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 2, 1998
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study TeamK Henry, A Erice, C Tierney, et al.
Pageof 11